MannKind Corporation
Use of ultrarapid acting insulin
Last updated:
Abstract:
Disclosed herein are improved methods of treating hyperglycemia with a combination of an ultrarapid acting insulin and insulin glargine comprising prandial administration of the ultrarapid insulin, and administration of a first dose of insulin glargine within 6 hours of waking for a day.
Status:
Grant
Type:
Utility
Filling date:
29 Jun 2018
Issue date:
15 Sep 2020